About us

Leading the discovery of GPCR modulating therapies

About Confo Therapeutics

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets.

This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.

Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.

GPCRs

G-protein-coupled receptors (GPCRs) are the largest family of human membrane proteins and play a central role in a wide range of biological processes. Despite this, many GPCRs remain therapeutically untapped due to a lack of understanding of their biology and function, as well as difficulties in identifying drug development candidates targeting these highly dynamic proteins.

TECHNOLOGY

Our proprietary technology platform uses conformationally selective V_HH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, facilitating the design of novel medicines with optimal properties. Empowered by our unrivalled Confo® technology and a world-class team of experts in GPCRs, structural biology, computer-aided drug design and medicinal chemistry, we aim to become leaders in the discovery and development of impactful GPCR-modulating medicines.

THERAPEUTICS & COLLABORATION

Our mission is to develop novel GPCR modulators for patients with severe and underserved diseases, with a current emphasis on rare diseases. Beyond developing our own pipeline of small molecules, we have secured revenue-generating drug discovery partnerships with leading pharma companies.

ORGANIZATION

As a spin out from the Vrije Universiteit Brussel (VUB) and Vlaams Instituut voor Biotechnologie (VIB) in 2015, we operate across two sites in Belgium, one in Ghent and the other in Brussels.

Led by an experienced and dynamic leadership team, we have raised over €40 million and are supported by a strong syndicate of international investors.

Headquartered in Belgium, Confo finds itself in the heart of a thriving ecosystem for biopharmaceutical innovation and success, which has set the stage for rapid growth in both the European and international biotechnology industries.